Cancer genomic profiling can be challenging for patients with limited tissue sample, especially in cancer types such as lung cancer where small biopsy samples coupled with low tumor cellularity are the norm. By performing macrodissection and utilizing our expertise in handling FFPE samples, ACT Genomics is able to offer high success rate in FFPE and provide more comprehensive information on copy number variation (CNV) and mutations, with a small amount of specimens.
ACTOnco® + comprehensive genomic profiling, ACT Genomics’ flagship panel, covers tumor mutational burden (TMB), microsatellite instability (MSI) status and immune-related genes to provide a more accurate prediction of ICI responses.
For every report, ACT Genomics provides one-on-one report consultation for ordering physician. Our user-friendly reports offer clinically significant insights through logically-organized content and intuitive graphics.
Identify More Evidence-Based Treatment Options
ACT Genomics panels are designed to support physicians with evidence-based and actionable insights to answer clinical challenges in cancer management. Identifying the genetic alterations harbored in the patient’s tumor and understanding how they affect cancer-related cell signaling pathways to drive tumor growth are the keys to finding suitable treatment strategies for each patient.
Comprehensive Genomic Profiling
Real-Time Monitoring with Liquid Biopsy
ACTMonitor® + uses circulating tumor DNA (ctDNA) to provide an early detection of cancer recurrence and drug resistance. ctDNA consists of fragments of DNA released from necrotic or apoptotic tumor cells into the blood stream. ACTMonitor® + detects the occurrence of variants that would lead to drug sensitivity or resistance, allowing assessment of treatment responses before changes can be observed by protein markers and in radioimages.
Cancer Monitoring
Real-time monitoring through blood specimen
Detects drug resistance
Assesses treatment responses
Identify High Risk Groups for Hereditary Cancer
Approximately 5-10% of cancers are caused by germline mutations. In addition to the well-characterized BRCA1/2, mutations in many other genes also cause a higher lifetime risk of cancer, up to 10-90 times higher than for someone without a mutation.
ACTRisk™ is a genetic test that analyzes 67 genes strongly associated with common hereditary cancers. It provides important genetic information that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with clients.
Hereditary Risk Evaluation
Analyzes 67 genes
Evaluates risk for 9 hereditary cancers and 11 cancer sydrome
The biomarker exploratory analyzed results of the phase 3 JAVELIN Bladder 100 trial 2020-10-22
Avelumab plus best supportive care (BSC) was demonstrated to prolong overall survival with first-line maintenance treatment in advanced urothelial carcinoma (UC) in phase 3 JAVELIN Bladder 100 trial. An exploratory analysis indicated that the combination
Poziotinib showed potential in treating NSCLC patients harboring an ERBB2 Exon 20 insertion 2020-10-22
In phase 2 ZENITH20 trial, poziotinib demonstrated anti-tumor activity in NSCLC patients who had an ERBB2 Exon 20 Insertion. Tumor reduction in 74% of patients.
An EGFR-MET bispecific antibody-Amivantamab(JNJ-372) combine with 3rd generation EGFR TKI-Lazertinib demonstrated safety and efficacy in a phase I trial 2020-10-22
The combination of amivantamab and lazertinib showed 36% ORR in Osimertinib resistant patients and 100% ORR in treatment naïve EGFR+ NSCLC patients with favorable safety profile.
A case series study of cancers with NRG1 gene fusion 2020-09-22
A case series study described six cancer patients with NRG1 gene fusion received afatinib treatment. Four patients achieved partial response. The results indicated NRG1 gene fusion is a potential druggable biomarker in clinical practice.
Olaparib and Durvalumab Combination Showed Promising Results in HER2-negative Breast Cancer Patients with Germline BRCA Mutation 2020-09-22
MEDIOLA is a phase I/II basket trial of olaparib and durvalumab. In a study cohort of the MEDIOLA study, the combination of olaparib and durvalumab showed promising anti-tumor activity in HER2-negative gBRCA-mutated breast cancer.
Ensartinib: A new TKI inhibitor prolonged PFS in ALK+ NSCLC patients 2020-09-22
In a phase 3 study (eXalt3), ensartinib showed longer mPFS and higher intracranial ORR compared with crizotinib. The results indicated ensartinib can be a new first-line treatment option for patients with ALK+ NSCLC.
Step 1.
We are highly experienced and possess professional high standard procedures in the challenging process of retrieving DNA from FFPE samples for sequencing. Our scientists have optimized the methodology to consistently achieve successful sequencing with highly accurate results. In addition to FFPE samples, our platform also works with core needle biopsies, pleural effusion, ascites, blood samples, and buccal swaps.
Step 2.
ACT Genomics has established a state-of-the-art next generation sequencing (NGS) platform. Sequencing is performed on Ion Personal Genome Machines, Ion Proton sequencers and Illumina MiSeq; ACT Genomics is an Ion Torrent™ Certified Service Provider.
Step 3.
ACT Genomics integrates advanced annotation and visualization tools, coupled with public and proprietary databases to deliver comprehensive and comprehensible reports.
Step 4.
With accurate genomic profiling, visualizing genes with alterations in known cancer pathways and providing potential matching cancer targeted treatments from FDA and National Comprehensive Cancer Network (NCCN) guidelines, mutated sub-network in known pathways, as well as references, ACT Genomics aims to deliver a concise, reliable and actionable meaningful clinical report.
